Today's Gilead Federal Circuit Decision Is a Significant Change to Double-Patenting Law

Today, the Federal Circuit issued an opinion altering the law of double patenting in Gilead Sciences, Inc. v. Natco Pharma Limited, No. 2013-1418, in a manner that will likely have a significant impact on the pharmaceutical industry. Chief Judge Rader provided a vigorous dissent and it remains to be seen whether the case will withstand petitions for rehearing en banc.

Click here for a PDF of the full text